NCT02619617终止2 期
A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Number of Participants With Headache Response (PD Analysis Set)
研究概览
简要总结
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
详细描述
The purpose of this non-confirmatory study was to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study was a sequential design of SOM230 vs. Placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is male or female age 18-65 inclusive.
- •Written informed consent must be obtained before any assessment is performed.
- •Subjects must have established diagnosis of episodic cluster headaches (CH) or chronic CH, averaging 2-6 headache attacks per day each lasting at least 45 minutes without treatment, not to exceed 6 attacks per day within the last year.
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study, as well as accepting NOT to share any study information through social media during their participation in the study.
- •Subject is able to self-inject medication subcutaneously or have the assistance of a partner on an out-patient basis.
排除标准
- •Subjects that have a history of greater than 6 CH attacks per day within the last year.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the duration dosing of the study treatment. Or men who are sexually active with women of child bearing potential, unless the male subjects always use condoms during the study.
- •History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.
- •Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations.
- •A history of clinically significant heart diseases, ECG abnormalities, continued use of drugs known to prolong QTc during the study conduct, or any of the following ECG abnormalities at screening or baseline:
- •QTcF > 450 msec (males)
- •QTcF > 460 msec (females)
- •Uncontrolled diabetes as evidenced by screening HbA1c > 8.0%
- •A positive Hepatitis B surface antigen or Hepatitis C test result.
- •A positive pregnancy test or lactating mothers.
- •History of drug or alcohol abuse within the 12 months prior to dosing other than prescription medications to manage their CH attacks, or evidence of such abuse as indicated by the laboratory assays conducted during screening.
- •Significant acute illness which has not resolved within two (2) weeks prior to initial dosing.
- •Any surgical or medical condition which might significantly jeopardize the subject's safety in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical or laboratory evidence of any of the following:
- •Liver disease or liver injury as indicated by abnormal liver function tests. ALT (SGPT), AST (SGOT), γ-GT, alkaline phosphatase and serum bilirubin will be tested.
- •ALT must be within the normal range
- •Serum bilirubin must not exceed 1.2 x ULN
- •γ-GT, AST and alkaline phosphatase must not exceed 2 x ULN [If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to treatment, to rule out any laboratory error]
- •Acute cholecystitis or symptomatic cholelithiasis in subjects without H/O cholecystectomy
研究组 & 干预措施
SOM230 0.9mg
Experimental
cohort 2
干预措施: SOM230 (Drug)
SOM230 0.9mg
Experimental
cohort 2
干预措施: Placebo (Drug)
SOM230 1.5 mg
Experimental
cohort 1
干预措施: SOM230 (Drug)
SOM230 1.5 mg
Experimental
cohort 1
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants With Headache Response (PD Analysis Set)
时间窗: 30 minutes post dose
Defined as very severe, severe, or moderate pain before dosing that becomes mild or nil at 30 minutes post-dosing
次要结局
- Number of Participants Who Were Pain Free at 30 Minutes Post Dose(30 mins post dose)
- Change in Hemoglobin Values From Screening to End of Study(screening and end of study, up to 9 days after treatment)
- Pulse Rate(screening and end of study, up to 9 days after treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pasireotide LAR in Severe Polycystic Liver DiseaseSomatostatin AnalogsAutosomal Dominant Polycystic Liver DiseaseAutosomal Dominant Polycystic Kidney DiseasePolycystic Liver DiseaseNCT01670110Mayo Clinic48
已完成
2 期
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor SizePrimary Inoperable ThymomaLocal Recurrent ThymomaNCT02021942Prof. Dr. Berthold Schalke16
已完成
3 期
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar LinesModerate to Severe Glabellar LinesNCT02353871Ipsen185
已完成
2 期
Monthly SOM230C for Recurrent or Progressive MeningiomaMeningiomaNCT00859040Patrick Y. Wen, MD34
已完成
2 期
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid CancerMedullary Thyroid CancerNCT01625520Federico II University19